Editorial: outcomes following a second switch-evaluating clinical outcomes and patient perspectives in IBD

Aliment Pharmacol Ther. 2021 May;53(9):1038-1039. doi: 10.1111/apt.16325.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal
  • Biosimilar Pharmaceuticals*
  • Humans
  • Inflammatory Bowel Diseases* / therapy
  • Infliximab
  • Prospective Studies

Substances

  • Antibodies, Monoclonal
  • Biosimilar Pharmaceuticals
  • CT-P13
  • Infliximab